Two-thirds of clinicians stop engaging with content after clunky interactions.
The offering lets employers subsidize employees’ cash-pay price—sidestepping opaque PBM rebates and helping rein in rising pharmacy costs.
Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.
Its pharma ad lawsuit against J&J’s promotions lands amid rising enforcement and shrinking tolerance for bold claims.
Novo’s drug candidate CagriSema lagged Lilly’s Zepbound in weight loss trials, sending Novo shares down 15% and widening Lilly’s market lead.
Quicker, reliable AI notes help clinicians reclaim minutes they can spend on patients, even as AI accuracy concerns persist.
Tragic news moves consumers’ health choices, signaling to healthcare marketers that they need to pay attention to key cultural moments, not just paid celebrity endorsements.
Justices curb Trump’s tariffs, but a national security case could sustain pharma import taxes.
Single-study clinical trials (versus two) become the default, speeding up common drug approvals, while vaccines still face tougher scrutiny.
After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.
The Eucalyptus deal deepens global reach as diversification beyond compounded GLP-1s in the US becomes urgent.
As AI tools steer more healthcare decisions, providers and insurers must target high-value use cases, carefully vet vendors, and lock in governance early.
Healthcare and pharma marketers should ramp up social listening and host expert Ask Me Anything sessions to drive engagement without feeling intrusive.
The FDA’s plans for broader access of medications could boost convenience, but also raise safety risks and drug costs.
Doctors watch less TV than the average US adult, but favor CTV and on-demand—which are prime time for targeted pharma messaging.
But as competition intensifies, high traffic isn’t enough—brands must pair visibility with proven product efficacy to convert surging consumer interest into loyalty.
Fraudulent care messages drive stress and confusion, pushing brands to rethink patient communication strategies.
India’s GLP-1 rollout next month signals tougher pricing ahead for GLP-1 brands.
Rising FDA enforcement pushes drugmakers to revisit messaging and risk framing.
Doctors must reassert personalized nutrition advice, while food brands should highlight their better-for-you offerings.